Sigma Planning Corp Acurx Pharmaceuticals, Inc. Transaction History
Sigma Planning Corp
- $3.07 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding ACXP
# of Institutions
31Shares Held
1.53MCall Options Held
13.6KPut Options Held
4K-
Vanguard Group Inc Valley Forge, PA529KShares$206,4460.0% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$142,9640.08% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$57,1350.0% of portfolio
-
Morgan Stanley New York, NY106KShares$41,4180.0% of portfolio
-
Vanguard Capital Wealth Advisors67.5KShares$26,3250.03% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $4.51M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...